AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — ...

AbbVie remains a Strong Buy due to robust growth in immunology and neuroscience portfolios, offsetting Humira's decline.

These stocks have been raising their dividend payments annually for well over a decade, and they pay more than twice the S&P ...

These days, the phrase “omnichannel engagement” is everywhere. But the way the biopharmaceutical industry thinks about ...

Piper Sandler 37th Annual Healthcare Conference December 3, 2025 8:30 AM ESTCompany ParticipantsDavid Amsellem - MD & Senior ...

Discover how the Impact of R&D on Biotech Companies in India is driving innovation, boosting exports and transforming pharma, ...

Pfizer's strategy that will help it rebound from recent struggles is in full motion. It says a lot that the company continues ...

The answer to why WBD is now popular is, as ever with Hollywood, the assets. It controls one of the richest pools of ...

Medicare Open Enrollment for Part D drug plans ends on December 7th. Don't miss this chance to change plans for 2026.